GlassScriptPhysician profile
Ted James Nifong
NPI 1063599587
$4,133.61
in general payments reported to CMS, 2019-2025
45 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $562 · 2021: $612 · 2022: $571 · 2023: $504 · 2024: $774 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $499.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $343.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.36 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $329.46 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $287.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $232.19 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $192.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $175.60 | 2019-2024 | Xarelto |
| Abbvie INC. | $168.68 | 2021-2025 | |
| Astellas Pharma US INC | $149.32 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $149.06 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $140.67 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $113.53 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Bayer Healthcare Pharmaceuticals INC. | $92.13 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $70.89 | 2019-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Nifong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.